Research ArticleTheranostics
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
Paul J. Roach, Roslyn Francis, Louise Emmett, Edward Hsiao, Andrew Kneebone, George Hruby, Thomas Eade, Quoc A. Nguyen, Benjamin D. Thompson, Thomas Cusick, Michael McCarthy, Colin Tang, Bao Ho, Philip D. Stricker and Andrew M. Scott
Journal of Nuclear Medicine January 2018, 59 (1) 82-88; DOI: https://doi.org/10.2967/jnumed.117.197160
Paul J. Roach
1Royal North Shore Hospital, Sydney, Australia
2Australasian Radiopharmaceutical Trials Network, Sydney, Australia
3University of Sydney, Sydney, Australia
Roslyn Francis
2Australasian Radiopharmaceutical Trials Network, Sydney, Australia
4University of Western Australia, Perth, Australia
5Sir Charles Gairdner Hospital, Perth, Australia
Louise Emmett
6St Vincent's Hospital, Sydney, Australia
7University of New South Wales, Sydney, Australia
Edward Hsiao
1Royal North Shore Hospital, Sydney, Australia
Andrew Kneebone
1Royal North Shore Hospital, Sydney, Australia
3University of Sydney, Sydney, Australia
George Hruby
1Royal North Shore Hospital, Sydney, Australia
3University of Sydney, Sydney, Australia
Thomas Eade
1Royal North Shore Hospital, Sydney, Australia
3University of Sydney, Sydney, Australia
Quoc A. Nguyen
8The Garvan Institute of Medical Research, Sydney, Australia
9Australian Prostate Cancer Research Centre—New South Wales (APCRC-NSW), Sydney, Australia
Benjamin D. Thompson
8The Garvan Institute of Medical Research, Sydney, Australia
9Australian Prostate Cancer Research Centre—New South Wales (APCRC-NSW), Sydney, Australia
Thomas Cusick
8The Garvan Institute of Medical Research, Sydney, Australia
9Australian Prostate Cancer Research Centre—New South Wales (APCRC-NSW), Sydney, Australia
Michael McCarthy
10Fiona Stanley Hospital, Perth, Australia
Colin Tang
4University of Western Australia, Perth, Australia
5Sir Charles Gairdner Hospital, Perth, Australia
Bao Ho
11St Vincent's Prostate Cancer Centre, Sydney, Australia
Philip D. Stricker
8The Garvan Institute of Medical Research, Sydney, Australia
11St Vincent's Prostate Cancer Centre, Sydney, Australia
Andrew M. Scott
2Australasian Radiopharmaceutical Trials Network, Sydney, Australia
12Austin Hospital, Melbourne, Australia
13Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia; and
14University of Melbourne, Melbourne, Australia
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 1
January 1, 2018
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
Paul J. Roach, Roslyn Francis, Louise Emmett, Edward Hsiao, Andrew Kneebone, George Hruby, Thomas Eade, Quoc A. Nguyen, Benjamin D. Thompson, Thomas Cusick, Michael McCarthy, Colin Tang, Bao Ho, Philip D. Stricker, Andrew M. Scott
Journal of Nuclear Medicine Jan 2018, 59 (1) 82-88; DOI: 10.2967/jnumed.117.197160
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
Paul J. Roach, Roslyn Francis, Louise Emmett, Edward Hsiao, Andrew Kneebone, George Hruby, Thomas Eade, Quoc A. Nguyen, Benjamin D. Thompson, Thomas Cusick, Michael McCarthy, Colin Tang, Bao Ho, Philip D. Stricker, Andrew M. Scott
Journal of Nuclear Medicine Jan 2018, 59 (1) 82-88; DOI: 10.2967/jnumed.117.197160
Jump to section
Related Articles
Cited By...
- Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
- The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer
- Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes
- Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment
- Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
- The Annual Journal Impact Factor Saga
- The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity
- Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
- Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
- 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
- Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer
- Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence--A Narrative Review of the Literature
- Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade
- Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis
- Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer
- 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients
- Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis
- Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
- The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer